Trade KLRS stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Kalaris Therapeutics, Inc. (KLRS) is trading at US$3.25, up 1.41% today as of Sep 21, 16:00 EDT. The company has a market capitalisation of US$98.79M. Over the past 52 weeks, KLRS has traded between US$3.03 and US$11.88. On Syfe you can trade KLRS with $0 commission and add it to your watchlist.
| Previous close | US$3.20 |
|---|---|
| Market cap | US$98.79M |
| 52-week range | US$3.03 – US$11.88 |
| Volume | 88.63K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company was founded by Srinivas Akkaraju, Mike Dybbs and Napoleone Ferrara in 2019 and is headquartered in Berkeley Heights, NJ.
Year: 2025
Kalaris Therapeutics Names Liisa Bayko CFO
Jul 20, 1:29 PM · MT Newswires
Top Midday Gainers
Jul 17, 5:51 PM · MT Newswires
Kalaris Says Additional Patients Show Improved Vision in Phase 1a Trial in Neovascular AMD
Jul 17, 11:44 AM · MT Newswires
TD Cowen Initiates Kalaris Therapeutics at Buy
Jun 15, 10:05 AM · MT Newswires
Wedbush Initiates Kalaris Therapeutics at Outperform With $17 Price Target
May 14, 11:48 AM · MT Newswires
Kalaris Therapeutics, Inc. (KLRS) stock is trading at US$3.25, +1.41% from the previous close of US$3.20.
The market cap for Kalaris Therapeutics, Inc. (KLRS) stock is approximately US$98.79M.
The 52-week high for Kalaris Therapeutics, Inc. (KLRS) stock is US$11.88.
The 52-week low for Kalaris Therapeutics, Inc. (KLRS) stock is US$3.03.
Kalaris Therapeutics, Inc. (KLRS) does not currently pay a dividend.
Stay on top of KLRS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
